DrugDashboards

Chlordiazepoxide and Amitriptyline Hydrochloride

chlordiazepoxide and amitriptyline hydrochloride · CHLORDIAZEPOXIDE 10 mg/1; AMITRIPTYLINE HYDROCHLORIDE 27.98 mg/1 · Tablet, Film Coated · Oral · Mylan Pharmaceuticals Inc.

NDC 00378-0277-01 · 100 TABLET, FILM COATED in 1 BOTTLE, PLASTIC · ANDA · View full market →

The short version

Only one company currently supplies this market — there is no backup if it stumbles. The price has held steady around $1.58 per unit over the past year. Put together: worth watching — several of the pressures that precede supply trouble are present at once.

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

One drug, every price

The same NDC has different prices depending on who is paying. Units differ between rungs — compare within a rung over time, not rung against rung, unless the units match.

ⓘ How this was built
Data sources
  • CMS NADAC (pharmacy acquisition, weekly)
  • CMS Part B ASP quarterly payment limits
  • CMS Maximum Fair Prices (IRA negotiated, NDC-level)
  • Medicare Part D Spending by Drug (data.cms.gov, name-matched)
  • VA FSS / Big4 federal contract prices (va.gov, twice monthly)
  • ACA Federal Upper Limits + weighted AMP (data.medicaid.gov, monthly)
  • California SB-17 WAC filings (list price, per package)
Method

Each rung is the newest figure for this NDC from one federal price system, shown with its own unit. Part D is matched by drug name because CMS publishes no NDCs there; it is gross spending, before confidential rebates.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

  • Pharmacies pay (NADAC)$1.58per EAinvoice-surveyed acquisition cost · Jun 18, 2025
  • Part D point of sale (median)$1.51per unitnegotiated price across 348 plans — before rebates · Apr 1, 2026
  • Federal contracts pay (FSS)$1.56per unitMylan Pharmaceuticals, Inc. · Jan 1, 202399% of what pharmacies pay — a deeper discount than 48% of drugs with this benchmark

Medicare Part D

All Part D pricing →
ⓘ How this was built
Data sources
  • CMS quarterly Prescription Drug Plan Formulary & Pricing files (SPUF)
Method

Negotiated 30-day point-of-sale unit prices and formulary terms aggregated across every unsuppressed Part D and MA-PD plan for the quarter shown. Point of sale means gross of confidential rebates. CMS publishes one representative NDC per drug concept (RxCUI) rather than every package, so these figures come from CMS's representative package for the same drug — matched on generic name, strength, and dosage form. Estimated from MedPAC's program-wide rebate aggregates (June 2023: DIR = 29% of gross Part D spending; brand rebates ≈ 25–40% of gross, generics minimal). Actual rebates are confidential and vary widely by drug — this is a range, not a fact about this drug.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

Plans pay at point of sale
$1.51per unit
middle half $1.34$1.59 · 348 plans · Apr 1, 2026
Est. net of rebates
≈ $1.51
generic — rebates are minimal, so net ≈ gross
Coverage & restrictions
6%of plans cover it
tier 2 · prior auth 39% · step therapy 0% · qty limit 0%

*No drug-level rebate is public — the estimate applies MedPAC's program-wide brand rebate range to this drug's gross price. Tracked here for 10 quarters since 2024.

NADAC price per unit

$0$1.00$2.00Nov 2013Jun 2025$1.58
53 price points · per EA · last surveyed Invalid DateSource: CMS NADAC

Estimated fill cost

#30 count
$47.32
#90 count
$141.96

Estimates: latest NADAC unit price × quantity. Pharmacy acquisition cost only — excludes dispensing fees, markup, and insurance terms.

Medicaid spend (2022)

$6,428
53 prescriptions paid by Medicaid nationally · all Medicaid spend →

Supply fragility

30Elevated risk

The score is counting real pressure here. One of these alone is routine; it’s the combination that makes this market worth watching.

  • 1 active manufacturer+30

The score counts pressure that is already visible — fewer makers, shortages, recalls, falling prices. 0 means none of it; 100 means all of it at once. Recomputed daily · as of Sep 3, 2026

90-day shortage risk (model v2)

0.1%chance of a new FDA shortage posting for chlordiazepoxide and amitriptyline hydrochloride (oral solid) in the next 90 days

sole-source market · price up 2% YoY

For scale: the typical drug’s chance is about 0.1% — this one is in ordinary territory.

Backtested statistical model over the whole market, not this package alone. Model details →

Regulatory

Application
ANDA071297
TE code
Approval date
Dec 10, 1986
Patents / exclusivity
None on file

Shortage history

No FDA shortage reports for this drug or its presentations.

Recalls (this NDC)

No enforcement reports list this package NDC.

Manufacturers of chlordiazepoxide and amitriptyline hydrochloride (Tablet, Film Coated)

LabelerStrengthFirst seenLast seen
Mylan Pharmaceuticals Inc.CHLORDIAZEPOXIDE 10 mg/1; AMITRIPTYLINE HYDROCHLORIDE 27.98 mg/1Aug 26, 2026Sep 2, 2026
Mylan Pharmaceuticals Inc.CHLORDIAZEPOXIDE 5 mg/1; AMITRIPTYLINE HYDROCHLORIDE 14 mg/1Aug 26, 2026Sep 2, 2026
Mylan Pharmaceuticals Inc.CHLORDIAZEPOXIDE 14 mg/1; AMITRIPTYLINE HYDROCHLORIDE 5 mg/1Jul 22, 2026Aug 19, 2026
Mylan Pharmaceuticals Inc.CHLORDIAZEPOXIDE 27.98 mg/1; AMITRIPTYLINE HYDROCHLORIDE 10 mg/1Jul 22, 2026Aug 19, 2026
Mylan Pharmaceuticals Inc.AMITRIPTYLINE HYDROCHLORIDE 14 mg/1; CHLORDIAZEPOXIDE 5 mg/1Jul 15, 2026Jul 15, 2026
Mylan Pharmaceuticals Inc.AMITRIPTYLINE HYDROCHLORIDE 27.98 mg/1; CHLORDIAZEPOXIDE 10 mg/1Jul 15, 2026Jul 15, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Chlordiazepoxide and Amitriptyline Hydrochloride — NDC 00378-0277-01," retrieved September 3, 2026, https://drugdashboards.com/drug/00378027701.

Free to cite with attribution — see how the data is put together.